SAN DIEGO, Feb 23, 2005 – Aethlon Medical, Inc. (OTCBB: AEMD) announced today that it plans to initiate clinical trials to treat patients infected with the Hepatitis-C Virus (HCV) in India. According to the World Health Organization, HCV is a global disease with approximately 170 million persons or 3% of the world’s population infected. It is estimated that up to 50% of the infected population is not responsive to treatment with current drug regimens.

Sunil Sawhney, the former Director of Boston Scientific India, and other regulatory advisors from Qualtran, LLC will manage the HCV trials in India, as well as trials related to the treatment of HIV, the AIDS virus. Site selection for both trials is underway, and patient enrollment is expected to begin in the coming months.

Aethlon CEO James A. Joyce stated, “Initiating studies to treat humans infected with Hepatitis-C is a natural progression of our science. Especially when considering the pre-clinical evidence that our Hemopurifier(TM) treatment technology has multi-pathogen binding capabilities, including the simultaneous capture of both HCV and HIV from the blood of infected patients.”